Estrogens promote lupus in humans and some mouse models of this disease. Nonetheless, little is known about the role of estrogen receptors in lupus pathogenesis. Here, we report that in females on the lupus-prone (NZB Â NZW)F 1 background, disruption of estrogen receptor-a (ERa or Esr1) attenuated glomerulonephritis and increased survival. ERa deficiency also retarded development of anti-histone/DNA antibodies, suggesting that ERa promotes loss of immunologic tolerance. Furthermore, ERa deficiency in (NZB Â NZW)F 1 females attenuated the subsequent development of anti-double-stranded DNA (dsDNA) IgG antibodies, which are associated with glomerulonephritis in this model. We provide evidence that ERa may promote lupus, at least in part, by inducing interferon-g, an estrogen-regulated cytokine that impacts this disease. ERa deficiency in (NZB Â NZW)F 1 males increased survival and reduced anti-dsDNA antibodies, suggesting that ERa also modulates lupus in males. These studies demonstrate that ERa, rather than ERb, plays a major role in regulating autoimmunity in (NZB Â NZW)F 1 mice. Furthermore, our results suggest for the first time that ERa promotes lupus, at least in part, by impacting the initial loss of tolerance. These data suggest that targeted therapy disrupting ERa, most likely within the immune system, may be effective in the prevention and/or treatment of lupus.
Introduction
A large body of evidence suggests that the preponderance of the autoimmune disease lupus in women is due in part to estrogens. Lupus onset is most common in women of reproductive age, whereas lupus onset is relatively rare before puberty or after menopause. Lupus risk is increased in men with Klinefelter's syndrome, a condition associated with increased serum estradiol. 1, 2 Abnormal estrogen metabolism leading to increased serum concentrations of certain estrogen metabolites with increased estrogenic activity has been observed in both men and women with lupus. [3] [4] [5] Epidemiological studies indicate that exogenous estrogens can increase lupus risk. [6] [7] [8] [9] Also, endogenous and exogenous estrogens may exacerbate lupus symptoms. [10] [11] [12] [13] Although several studies have observed an association between estrogen receptor-a (ERa) polymorphisms and lupus risk or age of onset, [14] [15] [16] this association is not found in all populations examined. 17 Thus, results from studies in humans indicate that estrogens enhance lupus development, but concrete evidence implicating the estrogen receptor-a and/or -b (ERa and ERb) in promoting lupus is lacking.
(NZB Â NZW)F 1 mice spontaneously develop anti-DNA antibodies and immune complex-mediated glomerulonephritis. 18, 19 As in humans, lupus development in (NZB Â NZW)F 1 mice is strongly influenced by gender; lupus incidence is higher and survival time is reduced in female (NZB Â NZW)F 1 mice relative to males. 18, 19 Exogenous estrogens accelerate autoantibody production and lupus development in male and female (NZB Â NZW)F 1 mice, [20] [21] [22] [23] whereas tamoxifen, which functions as an estrogen receptor agonist in some tissues but as an estrogen receptor antagonist in others, has been reported to significantly reduce autoantibody production 24 and mortality in (NZB Â NZW)F 1 females. 24, 25 These data suggest that estrogen receptor signaling promotes lupus development in (NZB Â NZW)F 1 mice. A recent study using ERa-and ERb-selective agonists in (NZB Â NZW)F 1 females suggests that activation of ERa, but not ERb, promotes lupus in this model. 26 Diamond and co-workers have demonstrated that exogenous administration of the naturally occurring estrogen, 17b-estradiol (E2), blocks tolerance induction of DNA-reactive B cells in the bone marrow of non-autoimmune BALB/c mice transgenic for the g2b heavy chain of the pathogenic R4A anti-DNA antibody. 27 Estradiol promotes the survival and activation of DNAreactive B cells by enhancing their resistance to B-cell receptor-induced apoptosis and decreasing the activation threshold for B-cell receptor signaling. 28 Estradiol administration also impairs immunologic tolerance induction in the spleen, leading to preferential selection of high-affinity DNA-reactive B cells into the mature B-cell pool. 29 Coadministration of estradiol and tamoxifen led to the appearance of maturation-arrested DNA-reactive B cells, 30 suggesting that blocking estrogen receptors inhibits the ability of estradiol to lower the activation threshold in DNA-reactive B cells but does not block estradiol-induced protection from apoptosis.
Collectively, the studies with tamoxifen in mouse models of lupus indicate that disrupting estrogen receptor function retards the ability of endogenous and exogenous estrogens to promote lupus. However, these studies do not permit a determination of the relative impact of disrupting ERa and ERb individually on lupus. Although estrogen receptors represent a major potential therapeutic target in the prevention and treatment of lupus, a greater understanding of the role each estrogen receptor plays in lupus development and pathogenesis is needed to maximize the efficacy of the development of novel therapies targeting estrogen receptor function. Although recent evidence suggests that selective activation of ERa signaling by exogenous administration of a receptor subtype-specific agonist significantly accelerates lupus in (NZB Â NZW)F 1 females, 26 the consequences of disrupting ERa signaling on this lupus-prone background are unknown. To gain insight into the role of ERa signaling in promoting lupus and to determine the consequences of disrupting ERa function on lupus, we investigated the impact of an ERa knockout on lupus development in (NZB Â NZW)F 1 mice. Our data indicate that targeted disruption of ERa is associated with attenuated development of glomerulonephritis and a dramatic increase in survival in (NZB Â NZW)F 1 female mice. We also demonstrate that ERa deficiency in (NZB Â NZW)F 1 females was associated with a significant reduction in the concentration of anti-histone/DNA and anti-double-stranded DNA (dsDNA) IgG antibodies. ERa deficiency in (NZB Â NZW)F 1 males was also associated with increased survival and a decrease in anti-dsDNA antibody development. These data indicate that ERa plays a major role in mediating the effects of endogenous estrogens in this model by promoting both loss of tolerance and the development of pathogenic autoantibodies.
Materials and methods
Generation of the NZB.ERaKO and NZW.ERaKO congenic lines Mice from N 12 backcross generation of the ERa-knockout strain (B6.129-Esr1 tm1Ksk ) 31 were provided by D Lubahn. Because the 129 strain, on which the original knockout was generated, carries alleles that impact lupus susceptibility, [32] [33] [34] it was important to identify any regions of residual 129-derived genome in the B6.129-Esr1 tm1Ksk strain, even though this congenic line was already extensively backcrossed. Therefore, we genotyped our original founder B6.129-Esr1 tm1Ksk animals using 61 markers spanning the 19 autosomes and the X chromosome (Table 1) . Oligonucleotide primers specific to simple sequence length polymorphism repeats that are polymorphic in length between the 129 and B6 mouse strains were obtained from Invitrogen Corporation (Carlsbad, CA, USA). Genotypes were determined as described previously, 35, 36 using DNA isolated from ear notches. The only residual 129 alleles detectable in these mice were at markers tightly linked to ERa, which resides on proximal chromosome 10 ( Table 1 ). The region of heterozygosity for 129 alleles surrounding ERa in this strain represents o48 Mb (1.7% of the genome) at a maximum. There is no evidence from crosses involving the 129 and B6 strains that chromosome 10 contains a locus that impacts lupus susceptibility. [32] [33] [34] Thus, the genetic background of this strain is more than 98% B6 and does not carry 129 alleles in any of the regions of the To generate the (NZB Â NZW)F 1 mice of the desired ERa genotypes, we produced two congenic mouse strains, one in which this ERa knockout (ERaKO) was carried on the NZB/BlNJ (NZB) genetic background and the other in which the ERa knockout was carried on the NZW/LacJ (NZW) genetic background. NZB.ERaKO and NZW.ERaKO congenic lines were produced using a modification of the marker-assisted selection method we have described previously. 36, 37 This approach utilizes genotyping to identify the progenitor of each generation, which is the individual in each backcross generation with the least residual heterozygosity. In the N 2 -N 4 backcross generations, genotypes at 30 polymorphic markers that define regions on eight chromosomes (Table 2 ) known to contain loci that control susceptibility to lupus in mice [38] [39] [40] [41] [42] [43] were obtained from mice that were heterozygous for the targeted disruption of the ERa gene (ERa
). In each of these generations, the ERa þ /À mouse from the incipient NZB and NZW congenic lines that carried the fewest number of residual B6 alleles in these eight defined intervals was chosen to produce the subsequent generation. In this way, the ERa knockout from the B6 strain was introduced onto both the NZB and NZW backgrounds free of B6 alleles at loci that are known to modulate murine lupus. [39] [40] [41] [42] [43] For production of these congenic lines, oligonucleotide primers specific to simple sequence length polymorphism repeats that are polymorphic in length between the NZB or NZW and B6 mouse strains were used. PCR genotyping was performed as described above. In the N 5 -N 9 backcross generations, the NZB.ERaKO and NZW.ERaKO strains were produced without genotype-based negative selection against B6 alleles.
The Institutional Animal Care and Use Committee of the University of Nebraska Medical Center approved all procedures involving live animals. Animals were housed under controlled temperature, humidity and 14 h light/ 10 h dark lighting conditions in a facility that is accredited by the American Association for Accreditation of Laboratory Animal Care and operated in accordance with the standards outlined in Guide for the Care and Use of Laboratory Animals (The National Academies Press, 1996). Mice were provided Harlan irradiated rodent diet 7904 (Harlan Teklad, Madison, WI, USA), which contains soy, milk and meat-based protein sources, and allowed to feed ad libitum.
Production and analysis of experimental mice At the N 7 -N 9 backcross generations of the NZB.ERaKO and NZW.ERaKO congenic lines, NZB females heterozygous for a targeted disruption of the ERa gene were crossed to NZW ERa þ /À males to produce ERa þ / þ , ERa þ /À and ERa À/À mice on the (NZB Â NZW)F 1 hybrid background. The ERa genotype of each mouse was determined using a previously described PCR-based assay.
Animals were monitored every 2 weeks for albuminuria using Albustix (Bayer Corp., Elkhorn, IN, USA) until they developed albuminuria, defined as two consecutive readings of 2 þ (100 mg per 100 ml), after which mice were monitored by Albustix weekly. Experimental mice were euthanized by CO 2 asphyxiation when albuminuria reached 4 þ (X2000 mg per 100 ml) or when animals reached at least 546 days (18 months) of age.
Histological analysis of glomerulonephritis
Kidneys were collected following euthanasia and fixed overnight in 10% neutral buffered formalin. Kidneys were then processed, embedded and sectioned. Multiple sections were stained with hematoxylin and eosin and evaluated for evidence of glomerulonephritis by light microscopy. Glomerulonephritis was assessed using a semiquantitative 0-4 scale, in which 0, 1, 2, 3 and 4 indicate that 0, 1-19, 20-50, 51-75, 475% of the glomeruli were affected, respectively. A score of 1 represents mild focal disease. A score of 2 represents moderate focal disease. Scores of 3 and 4 correspond to diffuse disease and as such were classified as 'severe glomerulonephritis.'
Serological analysis
Autoantibody development and concentration was assessed by enzyme-linked immunosorbent assay (ELI-SA) using serum isolated from blood collected monthly via the saphenous vein and stored at À80 1C. Samples were run in duplicate for each ELISA. Both semiquantitative ELISAs to assess total anti-dsDNA immunoglobulins and quantitative ELISAs to measure isotype-specific anti-dsDNA IgM and IgG concentrations individually were performed using kits from Alpha Diagnostics Corp. (San Antonio, TX, USA), according to the manufacturer's instructions. Quantitative data were obtained for each sample based on standards supplied by the vendor and were measured in units of mg ml
À1
. Anti-dsDNA IgG 1 , IgG 2a , IgG 2b and IgG 3 concentrations were determined using Immunolon 2 HB plates (Thermo Scientific, Waltham, MA, USA) coated with dsDNA (Sigma Aldrich, St Louis, MO, USA) that were prepared as described previously and assayed using alkaline phosphatase-conjugated IgG subclass-specific antibodies (Southern Biotech, Birmingham, AL, USA). The anti-total histone/DNA and anti-H2A/H2B/DNA concentrations were determined using plates prepared as described previously. 44, 45 Quantitative data for samples in these assays were obtained using a positive control sample, pooled serum obtained at the time of killing from a group of (NZB Â NZW)F 1 females with heavy albuminuria. These quantitative data are expressed in arbitrary ELISA units (U ml
). Total serum concentrations of antibodies of each isotype were determined using the clonotyping kit (Southern Biotech), according to the manufacturer's instructions. All optimal density measurements were made and analyzed using a BioRad 680 Microplate reader and Microplate Manager software, version 5.2.1. Sera were diluted serially from 1:100 to 1:2000 for measurement of autoantibody concentrations and to 1:50 000 for measurement of total serum immunoglobulins.
Serum interferon-g (Ifng) levels were assayed using the BD Cytometric Bead Assay Mouse IFN-g flex set, and data were acquired and analyzed using the BD FACSArray bioanalyzer and FCAP Array Software (BD Biosciences, Franklin Lakes, NJ, USA). Quantitative data were obtained for each sample based on standards supplied by the vendor and were measured in units of pg ml
. Sera were diluted from 1:4 to 1:10 for this analysis.
Quantitative reverse transcription-PCR Spleens were collected following euthanasia, immediately frozen in liquid N 2 and stored at À80 1C until use. Total RNA was prepared using the Absolutely RNA miniprep kit (Stratagene Corporation, La Jolla, CA, USA) and quantitated using spectrophotometry. cDNA was generated in reverse transcription reactions using TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, USA). The reaction mixtures were incubated at 25 1C for 10 min, 48 1C for 30 min and 95 1C for 5 min. Amplification of cDNA was performed using TaqMan Gene Expression Assays for Ifng (assay ID no. Mm00801778_m1) and TaqMan Endogenous Control Assay for Gapdh (part no. 4352932E) in the presence of 1 Â TaqMan Universal PCR Master Mix (Applied Biosystems). PCR was performed on the ABI 7500 RealTime PCR System using Sequence Detection Software, version 1.9 (Applied Biosystems). Reactions were incubated at 50 1C for 2 min and 95 1C for 10 min, and subjected to 40 cycles of PCR as follows: (1) 95 1C for 15 s and (2) 60 1C for 1 min. Quantitative data regarding gene expression were extracted from the PCR data for each sample using a standard curve. The abundance of Ifng transcript was normalized to that of Gapdh for each sample.
Statistical analysis
The impact of ERa genotype on latency to the development of albuminuria as well as lifespan was examined using Kaplan-Meier survival analysis and the log-rank test. For time-to-event data, median values were used when available. Proportions were compared between groups using Fisher's exact test. Differences in mean serum concentrations of antibodies, mean spleen weights and mean levels of gene expression were evaluated by t-test or one-way analysis of variance with Tukey's post hoc test, where appropriate. A two-sided Pp0.05 was considered evidence of statistical significance for these tests. Two-sided P-values are provided in the text.
Results
ERa deficiency inhibits albuminuria and enhances survival in (NZB Â NZW) females At the N 7 -N 9 backcross generations, NZB.ERaKO (ERa þ /À ) females were mated to NZW.ERaKO (ERa þ /À ) males to generate (NZB Â NZW)F 1 progeny of all three possible ERa genotypes. Analysis of the (NZB Â NZW)F 1 females suggested that ERa deficiency attenuates lupus development in these mice. Ninety-five percent of the ERa þ / þ (NZB Â NZW)F 1 females developed albuminuria, with a median latency of 201 days (Figure 1a ). Mean latency in this group was 238±23 days. Similarly, in the ERa þ /À (NZB Â NZW)F 1 females, 85% of the population at risk developed albuminuria with a median latency of 204 days and a mean latency of 226 ± 14 days (Figure 1a ). There was no difference in either the incidence of albuminuria or latency to onset of albuminuria in ERa þ / þ and ERa þ /À females (PX0.05). The symbols represent mice that were killed when they reached or exceeded 18 months of age. '1' and '2' indicate data significantly different than that in ERa þ / þ mice and in ERa þ /À mice, respectively. N ¼ 13-26 per genotype. For ERa þ / þ and ERa þ /À groups, representative histological sections of kidney from mice that were killed approximately at the group median for each genotype are illustrated. Sections from an ERa þ / þ female that was killed at 213 days of age (d) and an ERa þ /À female that was killed at 246 days of age (e) are shown. A section from an ERa þ / þ female that survived until 323 days of age is also shown (f). For ERa À/À (NZB Â NZW)F 1 females, sections from one mouse that was killed at 325 days of age (g) and another mouse at 538 days of age (h) are illustrated. Scale bars represent 100 mm. The white arrow, black arrow and arrowhead indicate a crescent, glomerular hypercellularity, and matrix deposition, respectively. ERa, estrogen receptor-a.
By contrast, the incidence of albuminuria in the ERa À/À (NZB Â NZW)F 1 females was only 54%, which was significantly less than that observed in both ERa
and ERa þ /À females (Pp0.01). Furthermore, median latency to the onset of albuminuria was 509 days in ERa À/À females (Figure 1a) , which was significantly greater than that in the ERa þ / þ and ERa þ /À females (Pp0.0001). The mean latency to the onset of albuminuria in ERa À/À females was 472 ± 35 days. These results indicate that ERa deficiency was associated with a reduced incidence of albuminuria and an increase in the median latency to onset of albuminuria in (NZB Â NZW)F 1 females.
ERa deficiency also had a dramatic impact on survival in (NZB Â NZW)F 1 females. The median lifespan in ERa þ / þ (NZB Â NZW)F 1 females of 238 days was not significantly different than that of 230 days in ERa þ /À females ( Figure 1b ; P ¼ 0.3). In both the ERa þ / þ and ERa þ /À (NZB Â NZW)F 1 females, the median survival time was approximately 25-40 days after the median onset of albuminuria. Mean survival in ERa þ / þ and ERa þ /À females was 289±27 and 257±15 days, respectively. These results are consistent with the mean lifespan observed historically in (NZB Â NZW)F 1 female mice, which ranges from B245 to B280 days of age. 18, 19 The mean lifespan in ERa À/À (NZB Â NZW)F 1 females was 470 ± 36 days, indicating that survival time was significantly greater in ERa
females, median survival could not be calculated since 54% of these mice survived to the final experimental end point of 546 days (18 months). The observation that ERa deficiency in (NZB Â NZW)F 1 female mice was associated with significantly increased lifespan is consistent with the fact that ERa deficiency led to a reduced incidence of albuminuria and increased latency to onset of albuminuria, an event that is directly correlated with morbidity and mortality in (NZB Â NZW)F 1 females.
Direct comparison of kidney pathology in ERa
and ERa þ /À (NZB Â NZW)F 1 females was complicated by the fact that lifespan in ERa À/À (NZB Â NZW)F 1 females was significantly increased relative to ERa
and ERa þ /À (NZB Â NZW)F 1 females. Therefore, the impact of ERa genotype on the incidence of severe glomerulonephritis at the time of killing was examined. At the time of killing, the kidneys of 100% of ERa þ / þ and 89% of ERa þ /À (NZB Â NZW)F 1 females showed histological evidence of severe glomerulonephritis, characterized by glomerular hypercellularity, matrix deposition and crescent formation, affecting 450% of glomeruli (Figures 1c-f) . The incidence of severe glomerulonephritis in ERa À/À (NZB Â NZW)F 1 females was 54%, which was significantly less than that in ERa þ / þ and ERa þ /À (NZB Â NZW)F 1 females (Figure 1c ; Pp0.05). Although the kidneys of these ERa À/À (NZB Â NZW)F 1 females did show histological evidence of severe glomerulonephritis (Figure 1g ), median survival in this subgroup was 371 days, indicating that nephritisassociated mortality in these mice did not occur until significantly later than that in ERa þ / þ and ERa
females, where median survival was 230-238 days of age (Pp0.05). The remaining 46% of ERa À/À (NZB Â NZW)F 1 females developed mild or moderate glomerulonephritis, with p50% of glomeruli showing glomerular hypercellularity and/or matrix deposition (Figure 1h ).
ERa deficiency leads to reduced serum anti-dsDNA antibody levels in (NZB Â NZW)F 1 females Because ERa deficiency was associated with attenuated nephritis in (NZB Â NZW)F 1 females, we evaluated the impact of ERa deficiency on the development of antidsDNA antibodies. Although the relationship between anti-dsDNA antibody concentration and glomerulonephritis severity is not absolute, these two parameters are well correlated in (NZB Â NZW)F 1 mice. 46 All
(NZB Â NZW)F 1 females (Figure 2a ; Pp0.05). Because these initial assays did not discriminate between the relatively innocuous anti-dsDNA IgM antibodies and the highly pathogenic anti-dsDNA IgG immunoglobulins, further assays were performed using isotype-specific antibodies. Because the mean antidsDNA antibody concentrations in ERa þ / þ and ERa
(NZB Â NZW)F 1 females did not differ significantly, only ERa þ / þ females were used for these comparisons with ERa À/À females. In this analysis of (NZB Â NZW)F 1 females, ERa deficiency was not associated with a change in serum concentrations of anti-dsDNA IgM antibodies (Figure 2b ; PX0.05). By contrast, the mean serum antidsDNA IgG concentrations in ERa þ / þ (NZB Â NZW)F 1 females at both 180 and 225 days of age were significantly greater than those in age-matched ERa (NZB Â NZW)F 1 females remained low up to and beyond 365 days (12 months) of age (data not shown). These data indicate that ERa deficiency is associated with attenuated development of highly pathogenic IgG anti-dsDNA antibodies. Furthermore, these data suggest that ERa deficiency may lead to enhanced survival and reduced incidence of severe glomerulonephritis in (NZB Â NZW)F 1 females by retarding the development of pathogenic anti-dsDNA IgG antibodies.
Our data are consistent with previous studies that have shown that in (NZB Â NZW)F 1 females less than 180 days of age, anti-dsDNA antibodies are primarily of the IgM class. 46 However, as these (NZB Â NZW)F 1 females age, there is a steady increase in the level of anti-dsDNA IgG. 46 The relative abundance of IgM to IgG anti-dsDNA antibodies can be expressed as a ratio (IgM/ IgG). The timing of the switch from predominantly IgM to IgG class, which is indicated by an IgM/IgG ratio of less than 1.0, correlates with the onset of overt glomerulonephritis. 46 In the ERa þ / þ females, the mean IgM/IgG ratio dropped to below 1.0 prior to 180 days of age (Figure 2d ), whereas the average IgM/IgG ratio in ERa À/À females remained above 1.0 beyond 270 days of age (Figure 2d and data not shown). Although antidsDNA IgM/IgG ratio in most ERa À/À (NZB Â NZW)F 1 females decreased to below 1.0 by 365 days of age, the anti-dsDNA IgM/IgG ratio in some ERa À/À (NZB Â NZW)F 1 females remained above 1.0 beyond this time point (data not shown). These results support the hypothesis that ERa deficiency significantly delays the onset of the switch from production of primarily IgM anti-dsDNA antibodies to predominantly IgG antidsDNA immunoglobulins.
Previous studies have shown that anti-dsDNA antibodies of the IgG 2a subclass are most closely associated with the development of glomerulonephritis in (NZB Â NZW)F 1 mice. 46, 47 Analysis of subclass-specific anti-dsDNA IgG concentrations revealed that ERa genotype had no impact on the mean anti-dsDNA IgG 1 and IgG 3 antibody concentrations (Figures 3a and d ERa deficiency is associated with reduced loss of tolerance to nucleosomal antigens in (NZB Â NZW)F 1 females Because estradiol has been demonstrated to break immunologic tolerance in a transgenic mouse model of lupus, 27 we also examined the effect of ERa genotype on the development of anti-H2A/H2B/DNA antibodies, which are associated with the initial breakdown of immunologic tolerance in lupus. 48, 49 For these experiments, serum concentrations of anti-H2A/H2B/DNA antibodies were determined in (NZB Â NZW)F 1 females at two early time points: B120 and B180 days of age. At 120 days of age, none of the experimental mice exhibited albuminuria. Although none of the ERa These results indicate that ERa deficiency is associated with a reduction in the loss of immunologic tolerance to nucleosomal antigens, which is associated with the initial development of autoimmunity in (NZB Â NZW)F 1 females.
To determine whether the effect of ERa deficiency on anti-dsDNA, anti-H2A/H2B/DNA and anti-total histone/DNA IgG concentrations was specific for these antigens or was the consequence of a more global defect in IgG production, we examined the effect of ERa deficiency on total serum immunoglobulins. We observed that the level of total immunoglobulins of each isotype and subclass in ERa þ / þ (NZB Â NZW)F 1 females did not differ significantly from that in age-matched ERa À/À (NZB Â NZW)F 1 females ( Figure 5 ; P40.05). These results indicate that ERa deficiency is not associated with a general defect in the maturation of the immune response or in the production of any IgG subclass.
ERa deficiency does not prevent splenomegaly in (NZB Â NZW)F 1 females Splenomegaly is a hallmark feature of several lupusprone mouse strains, including the (NZB Â NZW)F 1 hybrid. Although the underlying causes of splenomegaly in these strains are unknown, it is likely due to extramedullary hematopoiesis and/or lymphoproliferation. Thus, splenomegaly may represent a quantitative measure of lymphoid hyperactivity in these mice. Consistent with this idea, genetic studies indicate that loci controlling splenomegaly localize to the same regions of chromosomes 1 and 4 as loci controlling autoantibody levels and glomerulonephritis in lupus-prone strains. 38, 43, 50 Because ERa-deficient (NZB Â NZW)F 1 females exhibited reductions in (NZB Â NZW)F 1 females was significantly less than that in age-matched ERa þ / þ and ERa þ /À females (Figure 6a ; Pp0.05). Consistent with a previous report demonstrating that ERa deficiency is associated with reduced spleen size, 51 ERa deficiency was associated with reduced spleen size in young ERa À/À (NZB Â NZW)F 1 females, but ERa deficiency did not prevent the later development of splenomegaly in old ERa À/À females. At the time of killing, ERa þ / þ , ERa þ /À and ERa À/À (NZB Â NZW)F 1 females all exhibited significant splenomegaly (Figure 6b ). Direct comparisons of mean spleen weights between ERa À/À (NZB Â NZW)F 1 females and ERa þ /À or ERa þ / þ (NZB Â NZW)F 1 females were not made because the average age at the time of killing of ERa À/À (NZB Â NZW)F 1 females was significantly greater than that in ERa þ /À and ERa þ / þ mice (Figure 6b ). Despite these differences in average age at the time of killing, these data clearly indicate that ERa deficiency does not Impact of ERa deficiency on Ifng levels in (NZB Â NZW)F 1 females It has been shown previously that Ifng transcript expression is spontaneously induced in the spleen of (NZB Â NZW)F 1 mice well before disease onset, as early as 42 days of age. 52 The induction of this Th1 cytokine may promote the isotype switching of activated autoreactive B cells from IgM to IgG 2a . Because anti-dsDNA IgG 2a antibodies appear to be particularly pathogenic and contribute significantly to glomerulonephritis in (NZB Â NZW)F 1 mice, the induction of Ifng is thought to represent a key step in lupus pathogenesis in these mice. Consistent with this hypothesis, disruption of Ifng signaling ameliorates lupus in (NZB Â NZW)F 1 mice. 53 Because Ifng expression has been shown to be induced by estrogens in activated splenic B cells 54 and our own results demonstrated that ERa deficiency reduced anti-dsDNA IgG 2a concentrations, we postulated that ERa deficiency may attenuate the development of anti-dsDNA IgG 2a antibodies and attenuate lupus by reducing the spontaneous Ifng induction in (NZB Â NZW)F 1 females. Although estrogens have been shown to increase activity of the Ifng promoter in activated splenic B cells, 54 ERa genotype had no impact on either Ifng transcript level in the spleen (Figure 6c ) or serum Ifng level (data not shown) at 70 days of age. However, by B125 days of age, the mean serum Ifng level in ERa þ / þ (NZB Â NZW)F 1 females was significantly higher than that in ERa À/À females (Figure 6d ; Pp0.05). These data suggest that the ability of ERa to modulate autoantibody development and lupus in (NZB Â NZW)F 1 females may be mediated, at least in part, by the induction of Ifng.
ERa deficiency has an impact on albuminuria and survival in (NZB Â NZW)F 1 males Although the administration of exogenous estrogens has been shown to accelerate lupus development in (NZB Â NZW)F 1 males, 21 the impact of endogenous estrogens in (NZB Â NZW) males has not been determined. We observe that ERa deficiency is associated with a modest attenuation of lupus in (NZB Â NZW)F 1 males. Sixty-five percent of the ERa (NZB Â NZW)F 1 mice, 69% of the population at risk developed albuminuria with a median latency of 319 days (Figure 7a ). There was no difference in either incidence of or latency to albuminuria in ERa þ / þ and ERa þ /À mice (P40.05). The mean age at onset of albuminuria in ERa þ / þ and ERa þ /À males was 335±18 and 355 ± 22 days, respectively. Although the 46% incidence of albuminuria in ERa À/À (NZB Â NZW)F 1 males was less than that in the ERa
and ERa þ /À mice, this difference was not statistically significant. The median latency to the development of albuminuria was 476 days in ERa À/À males (Figure 7a ), which was significantly greater than that in ERa þ / þ and ERa þ /À males (Pp0.01). Mean latency to albuminuria in ERa À/À males was 481 ± 32 days of age. These results indicate that ERa deficiency is associated with an increased latency to albuminuria in males but has no significant impact on the incidence of albuminuria in males.
We also evaluated the impact of ERa deficiency on survival in (NZB Â NZW)F 1 males. The median lifespan in ERa þ / þ (NZB Â NZW)F 1 males of 321 days was not significantly different than that of 349 days in ERa þ /À mice ( Figure 7b ; P ¼ 0.5). Mean survival in ERa þ / þ and ERa þ /À males was 335 ± 16 and 354 ± 16 days, respectively. The median lifespan in ERa À/À males was 434 days, which was significantly greater than that in both ERa þ / þ and ERa þ /À males (Figure 7b ; Pp0.05). Mean survival in ERa À/À males was 435 ± 30 days. Within each genotypic class, the mean and/or median survival was slightly, but not significantly, less than the corresponding value for latency to albuminuria. This is likely due to mortality associated with the spontaneous development of lymphoma, which occurs in up to 30% of (NZB Â NZW)F 1 males. 55 As was observed in females, ERa deficiency had no significant impact on mean antidsDNA IgM concentrations (Figure 7c ) but led to a significant decrease in anti-dsDNA IgG concentrations (Figure 7c ; Pp0.05).
The impact of ERa genotype on the incidence of severe glomerulonephritis at the time of killing was examined in males. At the time of killing, the kidneys of 100% of ERa þ / þ and 83% of ERa þ /À (NZB Â NZW)F 1 males showed histological evidence of severe glomerulonephritis, characterized by glomerular hypercellularity, matrix deposition and crescent formation, affecting 450% of glomeruli (Figures 7d-f) . The incidence of severe glomerulonephritis in ERa À/À (NZB Â NZW)F 1 males was 75%, which did not differ significantly from that in either ERa þ / þ or ERa þ /À (NZB Â NZW)F 1 males (Figure 7d ; P40.05). Although the kidneys of these ERa À/À (NZB Â NZW)F 1 males showed histological evidence of severe glomerulonephritis (Figures 7g and h Absence of variability in genetic background of experimental (NZB Â NZW)F 1 mice The NZB.ERaKO and NZW.ERaKO strains used to generate the (NZB Â NZW)F 1 mice in this study were produced following strong negative selection against regions of the eight chromosomes known to contain loci that control susceptibility to lupus in mice ( Table 2) . No active or genotype-based selection against B6 alleles on the remaining chromosomes was performed in the development of these strains. Nonetheless, one would anticipate that random segregation alone would result in, on average, only 1.6-0.4% of markers retaining heterozygosity for B6 alleles at the N 7 -N 9 generations of these strains. Therefore, we anticipated that little residual B6 genome would remain in the NZB and NZW congenics. To explicitly test this prediction, the experimental (NZB Â NZW)F 1 mice used in the phenotypic analyses above were evaluated at 29 polymorphic markers spanning the unselected chromosomes and unexamined regions of the selected chromosomes ( Table 2 ). The (NZB Â NZW)F 1 mice were heterozygous for NZB and NZW alleles at all these markers, with three exceptions: one mouse was heterozygous for a B6 allele at a single marker (D12Mit60) and two mice were heterozygous for a B6 allele at another single marker (D19Mit103). These data support our hypothesis that very little residual B6 genome is retained in the NZB and NZW strains and suggest that the genetic background of the (NZB Â NZW)F 1 mice used in this study is highly uniform. Furthermore, because negative selection was applied to regions of the genome containing lupus susceptibility loci, we would predict that any remaining B6 alleles in these strains would not have a significant impact on lupus susceptibility or any related phenotype, such as anti-dsDNA antibody levels.
Discussion
Although tamoxifen has been demonstrated previously to attenuate lupus development in (NZB Â NZW)F 1 females, 24, 25 this is the first report that associates the disruption of ERa specifically with inhibition of lupus in (NZB Â NZW)F 1 females. Although ERa deficiency was associated with a decreased incidence of severe glomerulonephritis, more than half of the ERa À/À (NZB Â NZW)F 1 females did develop severe glomerulonephritis. However, the median time to nephritisassociated mortality in this subset was significantly greater than that in ERa 46, 47 These data suggest that ERa promotes lupus by enhancing the development of high levels of highly pathogenic anti-dsDNA immunoglobulins in (NZB Â NZW)F 1 females. The observation that ERa deficiency was associated with a reduction in antidsDNA IgG 2a immunoglobulins may also provide clues regarding the underlying molecular mechanisms through which ERa promotes lupus. The ability of Ifng to promote isotype switching to IgG 2a is thought to underlie, at least in part, the ability of this cytokine to stimulate lupus in (NZB Â NZW)F 1 mice. Consistent with this hypothesis, we observed that ERa deficiency was associated with reduced serum Ifng levels at an early time point. These data suggest that ability of ERa to modulate autoantibody development and lupus in (NZB Â NZW)F 1 females may be mediated, at least in part, on the induction of Ifng.
Although ERa deficiency had a major impact on antidsDNA IgG concentrations, no discernable effect of the knockout was seen on anti-dsDNA IgM concentrations. The observation that ERa deficiency was associated with reduced anti-dsDNA IgG, but not IgM, concentrations suggests that ERa may impact the maturation of DNAreactive B cells in these mice. ERa has been shown to be required for maintenance of post-natal thymic T-cell development 51, 56, 57 and maintenance of normal numbers of CD4 þ T helper cells. 57 Because CD4 þ T helper cells are essential for B-cell maturation and the production of IgG antibodies, these observations raised the possibility that ERa deficiency led to a reduction in lupus development in (NZB Â NZW)F 1 females, simply by reducing the number of CD4 þ T cells. Our observation that ERa deficiency did not impact total serum IgG concentrations argues against this possibility by demonstrating that the reduced numbers of CD4 þ T cells in ERa À/À mice do not lead to generalized defects in B-cell maturation or IgG production. However, our results do not rule out the possibility that ERa deficiency is associated with T-cell defects that, in a direct and specific manner, lead to reduced development of autoantibodies in (NZB Â NZW)F 1 females. Indeed, it is plausible that ERa deficiency may lead to differences in autoreactive T cells or T regulatory cells and that the selective effects on autoantibody production and isotype might reflect changes in these specific populations despite the absence of changes in the total number of CD4 þ T cells. The differential impact of ERa deficiency on anti-dsDNA IgG and IgM concentrations is also intriguing in the context of recent work demonstrating that administration of anti-dsDNA IgM antibodies to (NZB Â NZW)F 1 females can ameliorate disease symptoms. 58 These observations raise the possibility that ERa deficiency is associated with reduced incidence of severe glomerulonephritis in (NZB Â NZW)F 1 females not only because of reduced concentration of pathogenic anti-dsDNA IgGs but also high concentrations of antidsDNA IgM antibodies, which can exert protective action in the context of the lupus-prone (NZB Â NZW)F 1 background.
Our results illustrating that ERa deficiency is associated with reduced development of pathogenic anti-dsDNA antibodies likely explain the reduced incidence of severe glomerulonephritis and increased survival in (NZB Â NZW)F 1 females. However, the development of anti-DNA antibodies represents a relatively late event in the development of autoimmunity in these mice. The initial autoimmune response in these mice occurs months prior to the appearance of serum anti-dsDNA antibodies and is associated with loss of tolerance to histone H2A/H2B/DNA. 59, 60 Our results indicating that ERa deficiency is associated with reduced development of anti-H2A/H2B/DNA antibodies in (NZB Â NZW)F 1 females at this early time point suggest that ERa promotes the initial loss of tolerance event The symbols represent mice that were killed when they reached or exceeded 18 months of age. '1' indicates data significantly different than that in ERa þ / þ mice and '2' indicates data significantly different than that in ERa þ /À mice. AntidsDNA IgG concentrations were measured by ELISA at B315 days (c) and B365 days (data not shown) of age. N ¼ 13-31 (a, b) and 7-9 (c). The incidence of severe glomerulonephritis at the time of killing in each genotypic class is shown (d). For ERa þ / þ and ERa þ /À groups, representative histological sections of kidney from mice that were killed approximately at the group median for each genotype are illustrated. Sections from an ERa þ / þ male that was killed at 345 days of age (e) and an ERa þ /À male that was killed at 322 days of age (f) are shown. For ERa À/À (NZB Â NZW)F1 males, sections from one mouse that was killed at 329 days of age (g) and another male at 476 days of age (h) are illustrated. Scale bars represent 100 mm. dsDNA, double-stranded DNA; ELISA, enzyme-linked immunosorbent assay; ERa, estrogen receptor-a.
leading to lupus in these mice. Altogether, these data indicate that ERa promotes lupus development and pathogenesis in these mice by stimulating the initial loss of tolerance to H2A/H2B/DNA as well as the subsequent development of the highly pathogenic anti-dsDNA IgG antibodies. The development of anti-dsDNA IgG antibodies involves not only maturation of activated DNA-reactive, IgM-producing B cells but also epitope spreading, a poorly understood process by which autoreactive cells that respond initially to histone H2A/H2B/DNA evolve over time to obtain anti-dsDNA specificity. The molecular basis for the impact of ERa on each of these processes remains to be determined. Because ERa is expressed on B cells, T cells, dendritic cells and macrophages, future studies will be required to determine which cells are required for these ERamediated effects on lupus.
We also demonstrate that disruption of ERa has an impact on albuminuria, survival and anti-dsDNA IgG development in (NZB Â NZW)F 1 males. These results suggest that endogenous estrogens, signaling via ERa, also may play a role in promoting lupus in males. Although previous studies have shown that exogenous estrogens can accelerate autoantibody development and mortality in (NZB Â NZW)F 1 males, 21 this study is the first to provide evidence that endogenous estrogen signaling also impacts lupus in males in the context of any animal model of lupus. These results are consistent with studies in human lupus patients, which also suggest that endogenous estrogens promote lupus development in males. [1] [2] [3] [4] [5] Our results indicate that ERa deficiency is associated with reduced anti-dsDNA antibody development and glomerulonephritis on the strongly lupus-prone (NZB Â NZW)F 1 background. By contrast, it has been reported that this same targeted allele of ERa is associated with development of anti-dsDNA antibodies and immune complex-mediated nephritis in males and females at 1 year of age on a mixed B6/129 background. 61 However, our current studies have revealed no evidence of anti-dsDNA antibodies in 1-year-old ERa À/À mice on a genetic background, that is 485% B6 (KA Gould, unpublished data). One possible explanation for these disparate results is the interaction of the ERa disruption with strain-specific alleles that impact autoimmunity. In this context, it is important to note that the C57BL6 and 129 strains carry interacting alleles that promote autoimmunity. [32] [33] [34] Importantly, our results regarding the effect of ERa deficiency on the (NZB Â NZW)F 1 background are consistent with the existing data regarding the impact of tamoxifen on anti-dsDNA antibody concentration 24 and glomerulonephritis 25 in (NZB Â NZW)F 1 females. More significantly, our results are in concordance with the recent report of Li and McMurray, 26 demonstrating that an ERaselective agonist decreased survival and accelerated the development of anti-dsDNA IgG antibodies in (NZB Â NZW)F 1 females.
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